---
document_datetime: 2026-02-06 10:11:35
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mounjaro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mounjaro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 17.7192064
conversion_datetime: 2026-02-09 22:35:31.354816
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Mounjaro

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber      | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued²/ amendedon   | Product Information affected3   | Summary   |
|------------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA_IN / | E.4Changeinthenameand/or addressof | 05/02/2026                          |                                          | SmPC,                           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000315499                     | the marketingTerm name:E.4 authorisation holder, ASMF holder, storage site of the master and/or working cellbank, manufacturing site for an active substance, intermediate or finished product, primary and/orsecondarypackagingsite, manufacturerresponsible forbatch release, site where quality control takes place, and/or supplier of a packaging component, medical device (part), starting material, reagent and/or excipient (when mentioned in the dossier - E.4.a) The change in the name and/or address concerns the marketing authorisationholder-Accepted               |            | Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000269552 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.4 Change(s)in the Summary of Product Characteristics, LabellingorPackageLeafletduetonew quality, preclinical, clinical or pharmacovigilancedata-Accepted Updateofsection5.1of theSmPCinorder to update efficacy information based on final resultsfrom studyI8F-MC-GPHJ (SURMOUNT-5);thisis aPhase 3, randomised,open-label,activecomparator- controlledstudythatinvestigatedtheeffects of treatmentwith tirzepatide15mg orMTD (10mgor15mg)comparedwith semaglutide2.4 mg orMTD (1.7mg or 2.4 mg),in adult participantswhohad obesity or | 23/10/2025 | SmPC               | TheSmPCwasupdatedtoincludeinformationfrom trialI8F-MC-GPHJ(SURMOUNT-5).Inthis72-week trial, which included 751 adult patients with obesity (BMI30kg/m2)oroverweight(BMI27 kg/m2to<30kg/m2)with atleast1weight- related comorbid condition, treatment with tirzepatide (15 mg or 10 mg once weekly) resulted inasuperiorandclinicallymeaningfulreductionin body weight compared to semaglutide (2.4 mg or 1.7 mg once weekly).Tirzepatide also achieved superiority compared with semaglutide for the key secondaryendpoints,i.e.proportion ofpatients achieving≥10%,≥15%,≥20%,and≥25%body weightreduction atweek72aswell asreductionof waistcircumferenceatweek72.Formore information，pleaserefertotheSummaryofProduct |

<div style=\"page-break-after: always\"></div>

|                                          | overweight with weight-related comorbidities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |                 |                   |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|-------------------|
| Variation type IB /                      | B.1I.b.4 Change in the batch size (including batchsizeranges)of thefinishedproduct- B.I1.b.4.a Up to10-fold compared to the originally approvedbatchsize-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/11/2025 |                 | EMA/VR/0000310232 |
| Variation type IB / EMA/VR/0000264453    | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in themanufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process-Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediateusedinthemanufactureof the finishedproduct-B.II.b.3.a Minor change in the manufacturing process- Accepted B.II.b.4 Change in the batch size (including batchsizeranges)of thefinishedproduct- B.11.b.4.a Up to10-fold compared to the originallyapprovedbatchsize-Accepted | 06/05/2025 |                 |                   |
| Variation type IA_IN / EMA/VR/0000262378 | This was an application for a group of variations. B.II.b.2.cReplacementoradditionof a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/04/2025 | Annex II and PL |                   |

<div style=\"page-break-after: always\"></div>

|                                          | manufacturerresponsibleforimportation and/or batch release - B.I1.b.2.c.1 Not including batch control/testing - Accepted B.II.b.1 Replacement or addition of a manufacturingsiteforpartor all ofthe manufacturing process of the finished product - B.11.b.1.a Secondary packaging site - Accepted   |            |             |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type IA_IN / EMA/VR/0000275737 | B.II.b.2.cReplacement or addition of a manufacturerresponsibleforimportation and/or batch release - B.11.b.2.c.2 Including batchcontrol/testing-Accepted                                                                                                                                             | 04/06/2025 |             |
| Variation type II / EMA/VR/0000267397    | B.I.e) Design Space and post-approval change management protocols - B.I.e.2 Introduction of a post approval change managementprotocolrelatedtotheactive substance -Accepted                                                                                                                          | 13/11/2025 |             |
| Variation type IB / EMA/VR/0000272556    | B.II.b.4 Change in the batch size (including batchsizeranges)of thefinishedproduct- B.11.b.4.a Up to10-foldcompared to the originally approvedbatchsize-Accepted                                                                                                                                     | 17/06/2025 |             |
| PSUR/EMA/PSUR/0000288292                 | To be added                                                                                                                                                                                                                                                                                          |            | Maintenance |
| Variation type IA / EMA/VR/0000322709    | This was an application for a group of variations.                                                                                                                                                                                                                                                   | 15/01/2026 |             |

<div style=\"page-break-after: always\"></div>

| B.I.b.1 Change in the specification parameters and/or limits of an active substance,startingmaterial/intermediate/ reagent used in the manufacturing process of the active substance-B.I.b.1.d Deletion ofanon-significantspecificationparameter (e.g. deletion of an obsolete parameter) - Accepted B.I.a.3 Change inbatch size (including batch sizeranges)of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Upto10-foldincreasecomparedtothe originallyapprovedbatchsize-Accepted B.I.a.1 Change in the manufacturer of a startingmaterial/reagent/intermediateused in themanufacturingprocess of the active substanceorchangeinthemanufacturer (including where relevant quality control testing sites)oftheactive substance,where noPh.Eur.Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the activesubstance-replacement or addition of a site where batch control/testing takes place-Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance-Accepted   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| PSUR/EMA/PSUR/0000248506              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            | Based on the PRAC review of data on safety and efficacy,thePRACconsidersthattherisk-benefit balance of medicinal products containing tirzepatide remainsunchangedandthereforerecommendsthe maintenance of the marketing authorisation(s).   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000289603 | This was an application for a group of variations. B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier)-B.II.e.7.bReplacement or additionof asupplier-Accepted B.II.e.7 Change in supplier of packaging components or devices(when mentioned in the dossier)-B.1I.e.7.bReplacement or addition of a supplier - Accepted                                                                                                                                                              | 26/08/2025 |                                                                                                                                                                                                                                             |
| Variation type IB / EMA/VR/0000281959 | B.II.b.1 Replacement or addition of a manufacturingsiteforpartor allofthe manufacturing process of the finished product - B.11.b.1.f Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products(including those that are aseptically manufactured)excludingbiological/ immunologicalmedicinalproducts-Accepted B.1I.b.2 Change to importer, batch release arrangements and quality control testing off the finished product-B.1I.b.2.a | 31/07/2025 |                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                          | Replacement or addition of a site where batchcontrol/testing takesplace-Accepted                                                                                                                                                                                                                                                                                                                                                                                                           |            |      |                                                                              |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000261866 | B.I.e.5 Implementation of changes foreseen in an approved change management protocol - B.I.e.5.a The implementation of the change requires no further supportive data-Accepted                                                                                                                                                                                                                                                                                                             | 25/03/2025 |      |                                                                              |
| Variation typeIB/ EMA/VR/0000274140      | Thiswas anapplicationfor agroupof variations. B.II.e.6 Change in any part of the (primary) packagingmaterial not in contactwith the finished product formulation (such as colour offlip-off caps,colourcoderings on ampoules，changeofneedleshield(different plastic used)) - B.II.e.6.b Change that does not affect the product information - Accepted B.II.b.5 Change toin-process tests orlimits applied during the manufacture of the finishedproduct-B.II.b.5.zOther changes- Accepted | 25/06/2025 | PL   |                                                                              |
| Variation type II / EMA/VR/0000271741    | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.4 Change(s)in the Summary of Product Characteristics, LabellingorPackageLeafletduetonew quality, preclinical, clinical or pharmacovigilance data- Accepted                                                                                                                                                                                                                                                                                     | 24/07/2025 | SmPC | For more information, please refer to the Summary ofProduct Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                      | Update of section 5.1 of the SmPC in order to include3-yearefficacydatabasedonfinal resultsfromstudyI8F-MC-GPHK (SURMOuNT-1); this is a phase 3, efficacy andsafetyoftirzepatideonceweeklyin participants without Type 2 diabetes who have obesity or are overweight with weight- related comorbidities:a randomized,double- blind, placebo-controlled trial.                                                                                                                                                                                                                                                         |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation typeII / EMA/VR/0000271898 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.4 Change(s) in the Summary of Product Characteristics, LabellingorPackageLeafletduetonew quality, preclinical, clinical or pharmacovigilance data - Accepted Updateofsection4.6oftheSmPCinorder to include information on breast-feeding basedonresultsfromstudyI8F-MC-GPIN (GPIN); this was a Phase I, single-site, open-label, single-treatment arm, single- dose, lactation study, assessing pharmacokineticsoftirzepatideinbreastmilk and plasma in healthy lactating women.The Package Leaflet is also updated accordingly. The RMPversion6.1has alsobeen submitted. | 15/01/2026 | SmPC and PL | FollowingcompletionoftheGPINstudy,the recommendationonbreastfeedingwasamendedin the SmPC to reflect that, following a single 5 mg dose,theconcentrationof tirzepatideinbreastmilk wasfoundtobeundetectabletoverylowcompared toplasmaconcentrations.Astirzepatideisanamino acid sequence, any low amount present in breastmilkisexpected tobedegradedandnot orallyabsorbedasintactdrugbythebreastfed infant.Toprovidea completeoverviewofpotential consequences of Mounjaro use during breastfeeding,thepossibility that tirzepatide taken bythemothercouldindirectlyaffecttheinfantvia alteredbreastmilkcompositioninresponse to reducedmaternal food intakewas also added. Overall,tirzepatidecouldbeconsideredforuse during breast-feeding. For more information, please refer to the Summary of Product Characteristics. |
| Variation type IB /                  | B.I.a.1 Change in the manufacturer of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 19/06/2025 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000265586                     | startingmaterial/reagent/intermediateused in the manufacturing process of the active substanceorchangeinthemanufacturer (including where relevant quality control testingsites)oftheactivesubstance,where noPh.Eur.Certificate of Suitability is part of the approved dossier-B.I.a.1.z-Change in the manufacturer of AS or of a starting material/reagent/intermediateforAS-Other variation - Accepted   |            |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type IB / EMA/VR/0000314851 | B.II.b.4 Change in the batch size (including batchsizeranges)of the finishedproduct- B.I1.b.4.a Up to10-fold compared to the originally approved batch size - Accepted                                                                                                                                                                                                                                    | 19/12/2025 |
| Variation type IB / EMA/VR/0000314448 | B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where noPh.Eur.Certificate of Suitability covering theretestperiodispart of the approved dossier-B.I.d.1.z Other variation- Accepted                                                                                                                                                                    | 15/12/2025 |
| Variation type IB / EMA/VR/0000278526 | A.5Changeinthename and/oraddress of a manufacturer/importer of the finished product(includingbatchreleaseor quality control testing sites)-A.5.b The activities forwhich themanufacturer/importeris responsible do not includebatchrelease-                                                                                                                                                               | 27/08/2025 |

<div style=\"page-break-after: always\"></div>

|                                          | Accepted A. ADMINISTRATIVE CHANGES -A.4 Change in the name and/or addressof:a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate usedinthemanufactureoftheactive substance (where specified in the technical dossier)where noPh.Eur.Certificate of Suitabilityispartof the approveddossier;or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.II.b.1Replacement or addition of a manufacturingsiteforpartor allofthe manufacturing process of the finished product - B.11.b.1.z Other changes - Accepted   |            |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type IA_IN / EMA/VR/0000313865 | Thiswas an applicationfor agroupof variations. B.I.e.5Implementationofchangesforeseen inanapprovedchangemanagement protocol - B.I.e.5.a The implementation of thechangerequiresnofurthersupportive data - Accepted B.I.e.5 Implementation of changes foreseen inanapprovedchangemanagement protocol - B.I.e.5.a The implementation of thechangerequiresnofurthersupportive                                                                                                                                                                                                                                                                                                   | 25/11/2025 |

<div style=\"page-break-after: always\"></div>

| data -Accepted B.I.e.5Implementationofchangesforeseen inanapprovedchangemanagement protocol - B.I.e.5.a The implementation of the change requires no further supportive data-Accepted B.I.e.5Implementationofchangesforeseen inanapprovedchangemanagement protocol - B.I.e.5.a The implementation of the change requires no further supportive data-Accepted B.I.e.5Implementationofchangesforeseen inanapprovedchangemanagement protocol - B.I.e.5.a The implementation of the change requires no further supportive data-Accepted   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|